1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

'Medicare For All' Bills Prompt Warning From Former US FDA Commissioner Gottlieb

 
• By Sue Darcey

In an address to the National Press Club on 10 May, former FDA Commissioner Scott Gottlieb pointed to some of the challenges that CMS would face in supplying coverage for new technology, should a "Medicare for All" bill be adopted by Congress and signed by the president. Medtech Insight analyzed provisions that could impact industry in some of the proposed bills, in a comparative chart.

FDA Commissioner Scott Gottlieb discussed reimbursement challenges for medical products at the National Press Club in Washington, DC, with its President Alison Fitzgerald Kodjak.
Former FDA Commissioner Scott Gottlieb discussed challenges with "Medicare For All" bills at the National Press Club with club president Alison Fitzgerald Kodjak • Source: Michael Cipriano

Former US FDA Commissioner Scott Gottlieb, now an American Enterprise Institute scholar, told reporters at a National Press Club luncheon on 10 May that the device industry has good reason to be highly skeptical of expanding Medicare – as some so-called "Medicare for All" bills would do – and changing private coverage.

“I think it could squelch innovation and medical progress,” said Gottlieb, who left the top post at the agency on 5 April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

FDA Announces Classifications On 8 Device Types

 
• By Elizabeth Orr

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

State And International Enforcement Agencies May Step Up Amid Uncertain Federal Environment

 
• By Elizabeth Orr

States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.